Cancer Detection and Diagnosis Research in District of Columbia
Cancer Detection and Diagnosis Research (93.394) awarded $15.8 million to recipients in District of Columbia in 11 grants from fiscal 2021 to 2025, 0.6% of the program's national total. George Washington University (the) received the most, $6.5 million.
- Awarded in District of Columbia$15.8 million
- Awards11
- Share of the program0.6%
- Rank among states28th of 45
- National total$2.7 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 7 | $2.9 million |
| FY 2022 | 7 | $3.6 million |
| FY 2023 | 6 | $3.4 million |
| FY 2024 | 4 | $2.1 million |
| FY 2025 | 4 | $3.8 million |
Recipients in District of Columbia
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| George Washington University (the) | Colleges and universities | 3 | $6.5 million |
| Georgetown University | Colleges and universities | 3 | $4.2 million |
| Applikate Technologies, Inc. | Small businesses | 1 | $2.2 million |
| Children's Research Institute | Nonprofits | 2 | $2.0 million |
| Sesh Incorporated | Small businesses | 1 | $406,500 |
| Current Surgical Inc. | Small businesses | 1 | $400,000 |
Open opportunities under this program
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
See all 47 on the program page
Questions people ask
How much Cancer Detection and Diagnosis Research money goes to District of Columbia?
$15.8 million from fiscal 2021 to 2025, across 11 awards. District of Columbia ranks 28th of 45 states and territories for this program.
Who receives Cancer Detection and Diagnosis Research money in District of Columbia?
The largest recipient is George Washington University (the), with $6.5 million in 3 awards. Next are Georgetown University and Applikate Technologies, Inc..
Can organizations in District of Columbia apply now?
Yes, 47 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Detection and Diagnosis Research in other states
Other large programs in District of Columbia
- National Railroad Passenger Corporation Grants
- Grants to States for Medicaid
- USAID Foreign Assistance for Programs Overseas
- Federal-State Partnership for Intercity Passenger Rail
- Greenhouse Gas Reduction Fund: National Clean Investment Fund
- Federal Transit Formula Grants
- International Programs to Support Democracy, Human Rights and Labor
- Environmental and Scientific Partnerships and Programs
- International Broadcasting Independent Grantee Organizations
- Highway Planning and Construction